MediciNova (MNOV) announced that it has received a milestone payment under MediciNova’s assignment agreement with Genzyme Corporation, a subsidiary of Sanofi (SNY). The milestone payment of $1M is the result of the successful achievement of a clinical development milestone for a gene therapy product based on AAV vector technology that is covered under the assignment agreement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MNOV:
- MediciNova Receives Gene Therapy Milestone Payment
- MediciNova announces results of MN 166 studies under BARDA contract
- MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
- MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
- MediciNova’s abstact on MN-166 in glioblastoma selected for SNO presentation
